The BEET-BP Trial - Investigating the Effect of Dietary Nitrates on Hypertension in Pregnancy

Inclusion Criteria: * Aged ≥18 * Able to give written informed consent * Singleton pregnancies, between 24+0 to 36+6 weeks gestation with new onset gestational hypertension (defined by ISSHP2018 as new onset BP \>140/90 and no evidence of proteinuria, biochemical or haematological abnormalities or fetal growth restriction) Or * Singleton pregnancies, between 24+0 - 36+6 weeks gestation, with chronic hypertension (defined by ISSHP2018 as BP ≥140/90 predating the pregnancy or recognised at \<20 week's gestation) Or * Singleton pregnancies, between 24+0 - 36+6 weeks gestation, with preeclampsia (defined by ISSHP2018 as Gestational hypertension accompanied by ≥ 1 of the following new onset conditions at or after 20 weeks' gestation: * Proteinuria (24h urine collection\>300mg/day, Protein-creatinine ratio\>30 mg/mmol) * Other markers of maternal organ dysfunction, including: * Acute Kidney Injury (AKI) (creatinine ≥90μmol/L; 1mg/dL) * Liver involvement (elevated transaminases e.g. alanine transaminase (ALT) or aspartate aminotransferase (AST) \>40IU/L) with or without right upper quadrant or epigastric abdominal pain * Neurological complications e.g. eclampsia, altered mental status, blindness, stroke, clonus, severe headaches and persistent visual scotomata * Haematological complications (thrombocytopenia - platelet count \<150 000/μL, disseminated intravascular coagulation, haemolysis * Uteroplacental dysfunction (fetal growth restriction, abnormal umbilical artery doppler wave form analysis, or stillbirth) Exclusion Criteria: * Unable to tolerate taste of beetroot juice concentrate during taste test * Multiple pregnancy * History of acute or chronic liver conditions (aside from preeclampsia) * Fetal aneuploidies or major fetal anomalies * Unwillingness to comply with all study-related procedures e.g. Women who have used mouthwash or tongue scraping in last 7 days and are not able/unwilling unable to stop this for the duration of the study * Women on treatment for gingivitis * Women with persistent hyperemesis or ptyalism * On Proton-pump-inhibitors/antacids other treatment for gastritis/peptic ulcer/gastric ulcers * Those with long term antibiotic use e.g. prophylaxis of urinary tract infections (UTIs) or those who are likely to need repeated courses of antibiotics e.g. history of recurrent UTI * Women with known allergy/intolerance to beetroot or lemon * Type 1 and Type 2 diabetics * Moderate iron deficiency anaemia with haemoglobin \<100g/dL and/or ferritin \<15μg/L * Any blood disorder or significant illness that may affect platelet function and coagulation. However, patients taking low-dose aspirin (150mg) for preeclampsia prophylaxis who are at increased risk of developing preeclampsia will be included in the study. * History of alcohol or recreational drug abuse use within the past 6 months * Systemic autoimmune disease e.g. Rheumatoid Arthritis, antiphospholipid syndrome connective tissue disease e.g. Systemic Lupus Erythematous or other conditions known to be associated with chronic inflammation such as inflammatory bowel disease - Chron's disease/Ulcerative Colitis * Women not intending to deliver at the recruiting site * Participating in another intervention study that influences the outcomes of this study * Those with serious mental illness or learning difficulties and unable to give written informed consent * Those who are detained as a prisoner or detained in any secured unit, including those held under the Mental Health Act * Those not fluent in local language, and absence of appropriate interpreter despite use of services such as Language Line